Mohammad Humayun, Aliena Badshah, Iqbal Haider.
Effectiveness of Entecavir Or Tenofovir in Eradicating Chronic Hepatitis B Infection in patients with Superimposed Acute Hepatitis A/E/ Virus Infection.
J Med Sci Jan ;26(2):109-14.

Objective: To determine the effectiveness of Entecavir or Tenofovir in eradication of chronic Hepatitis B infection in patients with superimposed acute hepatitis A or E infection. Material and Methods: This simple, non-blinded randomized controlled trial was conducted in Department of Medicine, Khyber Teaching Hospital, Peshawar and the private practice of primary author from February, 2011 to April, 2017.702 chronic Hepatitis B patients of either gender, aged between 14 and 55 were recruited in the study after fulfilling the inclusion criteria. These patients were initially chronic Hepatitis B positive, but were not started on antiviral therapy owing to low viral counts. They subsequently developed acute hepatitis (either Hepatitis A or E).60% of the patients had positive hepatitis E serology, while 40% had positive serology for hepatitis A.These patients were divided into 3 wings: 1. 281 patients were started on Entecavir 0.5mg OD; 2. 281 patients were started on Tenofovir 300mg OD; 3. 140 patients who were willing to wait for spontaneous clearance of the virus were started on liver supplements used as placebo. These patients were followed at every 4 weeks for first 3 months and then every 6 months for the next 3 years. HBsAg clearance by 3rd generation ELISA, and negative HBV PCR at 12 months was taken as End Point of the study. Results were analyzed using SPSS 23 and expressed in percentages. Results: At the end of 6 months, 39.1% of patients started on either of Entecavir or Tenofovir achieved HBsAg clearance with negative PCR for Hepatitis B virus DNA, while only 3.3% of the placebo group achieved HBsAg negativity with negative PCR. At 12 months of initiation of treatment, 55% of patients started on either of Entecavir or Tenofovir achieved HBsAg clearance with negative PCR, while only 3.3% of the placebo group did. Conclusion: No statistical difference was found between Entecavir and Tenofovir in the management of Acute Hepatitis in Chronic Hepatitis B patients with superimposed acute Hepatitis A / E.Both entecavir and tenofovir were statistically significant as compared to placebo in the management of Acute Hepatitis in Chronic Hepatitis B patients with superimposed acute Hepatitis A / E.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com